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BACKGROUND AND RATIONALE
The HIV prevention research field has yielded a number of important new approaches during 
the last several years, including medical male circumcision, oral pre-exposure prophylaxis 
(PrEP), and treatment as prevention. Together with male and female condoms, prevention 
of mother-to-child transmission (PMTCT), and antiretroviral (ARV) treatment, these interven-
tions have the potential to help decrease the rate of new HIV infections and begin to curb the 
epidemic overall. At the same time, the need for women-centered products remains. Clinical 
effectiveness trials are under way for 1 percent tenofovir gel and the dapivirine ring, and 
research on other ARV-containing gels and rings continues. Given the urgent need for these 
products, the groundwork for introduction and rollout is being laid in parallel with clinical 
research. 
The Population Council, in collaboration with U.S. Agency for International Development 
(USAID) and other partners, is engaged in a program of research and action to prepare for 
the successful introduction of women-centered ARV-based HIV prevention methods. Following 
the results of the CAPRISA 004 trial, which demonstrated that tenofovir gel reduced the risk 
of HIV infection, USAID outlined a “Shared Vision”1 for access to microbicides that included 
development of an operations research agenda as one of its elements. 
Developing such an operations research (OR) agenda to prepare for the introduction of a 
new product is an important but often overlooked step. Clinical trials assess the safety and 
efficacy of medical interventions in tightly controlled settings; as such, they are not designed 
to address critical questions related to service provision under routine circumstances. Oper-
ations research generally identifies health system and service delivery issues and tests 
programmatic options for program managers and policymakers to consider when designing 
approaches to introduce or expand access to a product. 
To help shape this agenda, the Population Council drew on its long experience and expertise 
in microbicide product development and testing, as well as operations research in develop-
ing countries for family planning, reproductive health, and HIV/AIDS, all potential systems 
for microbicide delivery.2 Given that numerous other efforts are under way to address the 
delivery of oral Truvada for PrEP, and that clinical research on rectal microbicides is in earlier 
phases, this meeting focused specifically on gels and rings for vaginal use. While recognizing 
the significance of other biomedical interventions (such as male circumcision, oral PrEP, and 
treatment as prevention), the need for women-centered products remains critical. Making 
these products available requires a wide range of activities in areas including clinical testing, 
regulatory strategy, licensure, manufacturing, and financing. While all are key to delivering 
products, this meeting focused specifically on an operations research agenda for gels and 
rings. 
1USAID Proposal for a Shared Vision and Strategic Plan for Microbicide Introduction, May 24, 2011. http://transi-
tion.usaid.gov/our_work/global_health/aids/TechAreas/research/strategic_plan_microbicide_introduction.pdf.
2See, for example, Fisher, Andrew A. and James R. Foreit. 2002. Designing HIV/AIDS Intervention Studies: An 
Operations Research Handbook. New York: Population Council.
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MEETING PARTICIPANTS, AGENDA, FORMAT
The two-day meeting (17–18 June 2012) drew together nearly 40 diverse participants, with 
approximately half coming from a number of countries in Africa or India. Participants’ exper-
tise spanned operations research, microbicide clinical research and product development, 
AIDS care and services, policy and program implementation, and social and behavioral 
research. Council staff drew on their experience and a review of key documents and tools 
(see Appendix 1) to develop a list of potential operations research questions across a number 
of domains (see Appendix 2). Some of these questions are discussed more fully later in the 
report. To engage meeting participants with the issues and get an initial sense of priority and 
timing, the questions were sent to participants prior to the meeting for their feedback. 
Given the complexity and rapid evolution of the ARV-prevention landscape and the product 
pipeline, the first part of the meeting was devoted to reviewing recent results and develop-
ments in clinical testing, product development, acceptability, and regulatory review. Speakers 
also offered insights and analysis on lessons from other product introduction efforts, outlined 
the Population, Intervention, Comparison or Control, Outcome, and Time (PICOT) and Grading 
of Recommendations Assessment, Development, and Evaluation (GRADE) processes used by 
the World Health Organization (WHO) in weighing evidence to develop guidance, and offered 
a primer on operations research approaches, including highlighting the types of questions 
that OR can—and cannot—address. 
During lively discussion and debate, meeting participants worked to identify priority OR 
issues and began to outline how studies could be designed to address these questions. 
These discussions took place in the larger group as well as in breakout sessions where small 
groups identified key issues for the different technologies (gels and rings) and then outlined 
approaches to operations research on several priority topics. This report highlights the main 
themes identified in the presentations and discussions, and outlines ideas generated for 
priority research topics and approaches. 
WOMEN AND HIV PREVENTION: WHAT WORKS? 
The meeting began with an overview of biomedical, behavioral, and structural interventions 
currently available to women to reduce their risk of HIV infection. A comprehensive review 
of evidence on “what works for women” (www.whatworksforwomen.org) undertaken by the 
Futures Group notes a number of strategies to help women prevent HIV, including male and 
female condom use, reducing the number of partners, and treatment for sexually transmitted 
infections. Treatment as prevention also offers a promising new approach, though questions 
remain about its implementation in resource-limited settings.3 The review also notes that pre-
3Based on recent research and resulting regulatory and policy guidance, pre-exposure prophylaxis may also pro-
vide an important prevention strategy for women. However, it is not yet included in www.whatworksforwomen.org.
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vention efforts for married women have been neglected, although married women may be at 
increased risk of HIV. The review suggests that efforts be increased to meet women’s repro-
ductive health needs, including increasing condom use, sexuality education and communi-
cation, especially among young people. Overall, it highlights the limitations of approaches 
currently available and the need for more biomedical and structural tools, options, and 
approaches to empower women to help prevent HIV. The review underscores the importance 
of the consultation as part of efforts to develop and make rapidly available gels, rings, and 
other new technologies for women. 
LESSONS FROM OTHER HEALTH TECHNOLOGIES
Experience with introducing other health technologies provides a number of useful lessons 
that can be applied to ARV-based prevention for women, although no existing product offers 
a precise model. A number of lessons can be drawn from emergency contraception, contra-
ceptive vaginal rings, the female condom, HPV vaccine, and HIV treatment. Overall, across 
time, setting, and products, women’s overarching questions about new reproductive health 
technologies, including those for HIV prevention, are relatively straightforward and center on 
whether a product works, whether it causes harm (to the woman, her partner, or her baby), 
whether it will jeopardize future fertility, and whether it will disrupt her relationship with her 
partner. 
Although women’s unmet need for modern contraception may appear to be attributable to 
problems with access, a 2011 analysis showed several other issues as central: concerns 
about health or side effects, opposition from the woman or her partner, and infrequent sex.4 
This may suggest that coitally dependent products could fill an important niche, in contrast 
with concerns that women will struggle to use such products consistently. 
Emergency contraception (EC) shares a number of attributes with peri-coital gel use: both 
are user initiated, time sensitive, and require information and understanding to be used 
effectively. Women use EC even when other highly effective contraceptive products are 
available, and express interest in peri-coital methods. Although emergency contraception 
continues to be stigmatized in many settings, women still want it and generally prefer to have 
on-demand pharmacy access. Multiple brands are on the market in different settings, sug-
gesting both a continued “unmet need” and its commercial viability. Finally, while making EC 
available without a prescription has expanded access, such availability does have its down-
sides, making it difficult to monitor product safety and quality and to provide counseling. It 
also requires that women have funds available to purchase the product. 
Contraceptive vaginal rings can offer some clear lessons and parallels for ARV-containing 
rings. Protocols and duration of use vary among rings currently on the market which include 
4Darroch, Jacqueline E., Guilda Sedgh, and Haley Ball. 2011. Contraceptive Technologies: Responding to Women’s 
Needs. New York: Guttmacher Institute.
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monthly and three-month rings. While such rings do not require action daily or at the time of 
sex, they do require user effort. Experience with rings dates back decades, but most data is 
from the US and Europe and there is a need both to mine and perhaps generate more data 
on women’s experience with rings in a variety of settings. One important issue is expulsion 
and slippage among women with different reproductive histories, which needs to be docu-
mented and proactively addressed with users. 
The female condom (FC) is often cited as an important example for microbicide introduction 
and there are clear parallels and lessons from this coitally related, user- dependent, vaginally 
inserted method. The female condom was subject to strong provider and policymaker bias, 
which, coupled with relatively high production costs, resulted in a cycle of low demand and 
high cost. Like the gels and rings being developed for vaginal use, the FC is not a perfect 
product. Many women can and do use the FC, however, especially if they are supported as 
they become accustomed to and experienced with it; user education includes communication 
and negotiation skills and information on sexuality and anatomy. Consistent use, while opti-
mal, is difficult for many women to achieve, suggesting that HIV prevention products should 
ideally be provided together as a range of options so users can choose and switch among 
strategies to maximize their overall protection.
Finally, efforts to introduce ARV-based gels and rings should be informed by the extraordi-
nary global efforts to roll out HIV treatment and care. Maintaining adherence for any health 
intervention over time is challenging, and it is important that program approaches acknowl-
edge that incomplete adherence is normative for both treatment and prevention while at 
the same time developing, testing, and implementing approaches to bolster adherence. HIV 
testing is the gateway for use of ARV-based prevention and for antiretroviral therapy, and both 
approaches will require medical monitoring. All of the issues outlined above have implications 
for determining which service-delivery settings will be feasible, the periodicity of testing and 
resupply, what types of provider will be permitted to deliver the service, and scalability. 
These examples and others underscore that product introduction efforts need to demon-
strate that health systems and providers have the capacity to deliver the product safely and 
effectively; that the product and program are affordable and acceptable to users, programs, 
and funders; and that key (and potentially diverse) user groups can access and use the 
product as well as the program that delivers it. A vision needs to be presented for how a 
given product (such as tenofovir gel or the dapivirine ring) fits into the overall HIV prevention 
landscape globally and in specific settings, and satisfactory answers must be developed to 
address any concerns. 
Drawing on a number of analyses, including a previous Council meeting and publication on 
this topic,5 the relevant lessons and insights that can be applied to microbicide introduction 
are relatively clear and can inform operations research and program design for delivering 
ARV-based gels and rings without a great deal of additional analysis. Incorporating these 
lessons into program design will require vision, commitment, and investment. 
5Brady, Martha, and Elizabeth McGrory. 2007. “Insights and evidence from product introduction: Lessons for  
microbicides,” Day of Dialogue. New York: Population Council.
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WHERE ARE WE WITH MICROBICIDES? 
Product pipeline and lead products 
A review of the microbicide pipeline provided background information on the status of various 
product leads, focusing on 1 percent tenofovir gel and the dapivirine ring, the products fur-
thest along in development. FACTS 001, a safety and effectiveness trial of 1 percent tenofovir 
gel, is currently under way in South Africa with results expected in 2014. Two effectiveness tri-
als of 1 percent tenofovir gel have been conducted, with one showing a 39 percent reduction 
in risk of HIV acquisition (CAPRISA 004) and the other showing no effect (VOICE). A different 
formulation of 1 percent tenofovir gel is also being developed for rectal use. Two safety and 
effectiveness trials of the dapivirine ring, a sustained-release device, are expected to report 
results in 2015 (ASPIRE and the Ring Study). For both of these lead products, additional stud-
ies will provide data on safety during pregnancy and when breastfeeding, use in adolescents, 
drug interactions, manufacturing, and other issues necessary for licensure. The Population 
Council, CONRAD, and other groups continue research and development on other product 
leads, some of which are also multipurpose prevention technologies designed to also act as 
contraceptives. 
This timeline suggests that ARV-based gels and rings will be introduced into an increasingly dynamic and complex  
environment of prevention approaches with implications for service delivery, user education and action, and investment. 
2010 2011 2012 2013 2014 2015 2016















HIV Prevention Options Timeline * ** AVAC, September 2012
. 
.
Bangkok Tenofovir Study/CDC 4370















iPrEx2007 iPrEx Open-Label Extension (OLE)
2009 FEM-PrEP
US FDA filing and decision
CAPRISA 0042007
2007 TDF2 Open-Label ExtensionTDF2/CDC 4940

























































d5 2009 HVTN 505
* Trial end-dates are estimates; due to the nature of clinical trials the actual dates may change. For full trial details, see www.avac.org/trials. 
** Not all trials  included are eectiveness trials. Trials included on this list are mainly phase II/IIb, III/IIIb and IV trials.
Updated timeline available at www.avac.org/ht/a/GetDocumentAction/i/46212
 6  ■  Shaping the OR agenda for ARV-based prevention products for women: Gels and rings
Acceptability and use
Ongoing product development for gels and rings for HIV prevention has been accompanied 
and informed by acceptability research at all phases of preclinical and clinical development. 
This research has been conducted within and outside of clinical trials. Acceptability research 
to date indicates that overall women are quite positive about the products being tested and 
that although different women have different preferences, all delivery forms are acceptable. 
Some women are interested in using a product without telling their partner(s), although 
involving male partners is important for some women and in some settings. Cultural norms 
including those for “tight” or “dry” sex have not negatively affected acceptability, and in fact 
many women in trials (and their partners) report that microbicide gels make sex more com-
fortable and pleasurable. Acceptability needs to be assessed and addressed for providers, 
policymakers, and other key decisionmakers as well as users. Important dimensions for 
acceptability go beyond basic product characteristics and include issues like storage and 
disposal. 
Clinical trials offer a critical opportunity to learn about acceptability, and rich datasets exist 
from completed clinical trials as well as those being generated in ongoing trials. Additional 
information may be available from research and from the introduction of related technologies 
like contraceptive vaginal rings. In many cases, these data have not been thoroughly ana-
lyzed or applied, and they should be exploited to frame further studies and inform any future 
introduction efforts. At the same time, it is unclear how findings from trials will translate to 
ongoing use in routine service settings, so further research may be needed to assess dimen-
sions of acceptability as products are phased into wider use. 
OPERATIONS RESEARCH: WHAT IT CAN AND CANNOT DO
A review of operations research underscored that while there is some fluidity in definitions, 
parameters, and terminology, in general OR looks at the health system as the unit of anal-
ysis and seeks to measure outcome indicators for service delivery that are meaningful for 
program design, budgeting, and management. OR generates evidence to guide policy, pro-
gramming, and budgeting for service delivery, and different types of research are needed to 
generate different types of evidence. OR produces evidence on issues like the delivery attri-
butes for the provider, system, and user; system requirements and functioning for effective 
service delivery; parameters for policy support and delivery; and commodities logistics, cost, 
and prices. As such it complements research that is biomedical, clinical, or oriented to user 
behavior and acceptability. At the same time, not all problems or questions related to service 
implementation need to be addressed by research-based evidence, and it is important to 
ensure that research approaches match the questions they are seeking to address. 
Operations research studies need to clearly define and understand potential audiences and 
how they would use the evidence generated, as well as the systems adjustments needed for 
introducing and implementing any operational changes indicated by the OR findings. Specific 
questions can be addressed through nested studies and multisite studies, as the OR itself 
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should not be disaggregated into too many smaller, discrete studies. Developing OR should 
involve the end users of the research (for example, the Ministry or system responsible for 
implementation) and should include both plans and budget for extended actions beyond the 
study period to support institutionalization and scale-up of activities indicated by research 
evidence. Given this, the cycle for an OR project can often stretch for several years—time to 
understand the evidence needed and design the OR study, prospectively conduct an assess-
ment or evaluation of a service-delivery intervention, and then time to support the health 
system with institutionalization and scale-up of the organizational changes suggested by the 
OR findings. 
WHO GUIDANCE
WHO guidance will be critical to shaping country policy in many settings and is an essential 
step toward inclusion on WHO’s Model List of Essential Medicines and for launching the 
prequalification process. WHO is planning to establish a Guideline Development Group by 
the end of 2012, with a target of having guidance ready for publication soon after the first 
licensure decision on 1 percent tenofovir gel. The detail and specificity of guidance that can 
be issued depends on the extent of evidence available to inform that guidance. WHO antici-
pates that the Guideline Development Group will agree on a limited number of critical ques-
tions that need to be answered in order to issue initial policy guidance. These questions can 
also be used to inform priorities for operations and implementation research that needs to be 
completed in time for the results to be reflected in the guidance. 
WHO uses the Grading of Recommendations Assessment, Development, and Evaluation 
(GRADE) approach to review and weigh the evidence on which the guidance is based. It rates 
the quality of evidence on a number of parameters (study design, risk of bias, completeness 
of follow-up, imprecision, inconsistency, indirectness, and the magnitude of the effect), and 
grades the strength of recommendations (high, moderate, low, very low). In this system, evi-
dence from randomized controlled trials is initially rated higher than evidence from observa-
tional studies, but the factors mentioned above are used to increase or decrease the quality 
of evidence scores. This approach, initially developed to assess clinical evidence, presents 
challenges with respect to incorporating evidence from OR. Randomized controlled trials 
are generally inappropriate designs for operations research for reasons that include: the 
practical and ethical challenges with random assignment, large sample sizes, and controlled 
implementation; and experimental conditions that are unlike routine service settings. But OR 
has greater external validity and addresses key policy questions necessary to inform guid-
ance and country policies. It is important to note that WHO normative guidance addresses 
policy questions, such as whether a particular product or policy should be introduced into 
programs, and if so how, based on a wider assessment of risks, costs, and opportunity costs. 
This is distinct from the role of national regulatory authorities which assess safety and effi-
cacy of a new product in order to grant market authorization and thus allow the product to be 
marketed within their jurisdiction.
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The GRADE “PICOT” (Population, Intervention, Comparison or Control, Outcome, and Time) 
approach is designed to clearly define the questions for which evidence is systematically 
compiled and assessed. Policy questions to be addressed through the PICOT approach often 
have very limited information to support a recommendation, particularly for new products 
for which there is no, or limited, programmatic experience. But operations research that 
addresses questions on how to deliver a gel or ring safely and consistently, user preferences 
for different HIV prevention products, and identifying niche(s) where the product will be used 
effectively and have the greatest acceptability and impact would be very valuable to inform 
guidance. The framework and approaches WHO is currently developing for oral PrEP demon-
stration projects may be useful for framing OR on gels and rings, and staff at WHO and others 
interested in microbicide OR and implementation should stay apprised of these efforts. 
Experience with developing operations research and policy guidance with oral PrEP will also 
inform research on introduction of gels and rings. 
PRIORITY TOPICS, SELECTED QUESTIONS,  
AND EXPERT FEEDBACK
Participants identified a number of priority topics for operations research both prior to and 
during the consultation. Much of the discussion focused on models for service delivery, 
timing, and the use of proxy products, approaches to conveying partial effectiveness, and 
bolstering adherence. 
Sample questions for expert review
Drawing on the Council’s expertise and a review of key tools, reports, and literature (see 
Appendix 1), Council staff developed a number of questions related to operations research 
across a range of domains (see boxes in this section for select questions and Appendix 2 for 
the full survey): 
•	 Service delivery models 
•	 Providers
•	 HIV testing and retesting 
•	 Potential resistance
•	 Adherence
•	 Vaginal ring–specific issues
•	 Vaginal gel–specific issues 
•	 User perspectives and education
•	 Program costs 
These questions were sent to participants prior to the meeting, and participants were 
asked to rate the questions by level of importance (high, medium, low) and to indicate when 
research could or should be initiated to address the issue (actionable now, or after a prod-
uct is approved and available). Responses received were compiled prior to the meeting and 
presented to meeting participants for an overall sense of priorities and to help jump-start the 
discussion and debate.
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Most items were rated “high” to “medium” 
priority, with some ranked “high” but not 
actionable now. With regard to timing, for 
many questions it was difficult to make 
clear distinctions as to when a question 
could and should best be explored. For 
a number of topics, research conducted 
while clinical trials are ongoing could yield 
important findings and insights, which 
could then inform additional work or 
research in more routine service settings. 
The time between demonstration of clin-
ical efficacy and formal approval and/or 
widespread availability may be particularly 
fruitful for operations research to inform 
program design and implementation. 
Priority areas
Priority questions focused primarily on 
identifying appropriate service-delivery 
models and approaches for reaching 
different potential user groups, including 
the types of program entry points (such 
as reproductive health, antenatal care, 
HIV counseling and testing, school-based, 
etc.). Other priorities concerned related 
service issues such as the level of pro-
vider who could safely and appropriately 
deliver ARV-based prevention products, 
the kind of medical monitoring that would 
be required, and the feasibility and need 
for monitoring potential resistance. It 
will also be important to understand the 
implications of periodic HIV testing (for 
screening for initiating product use as well 
as for ongoing monitoring of HIV status) 
on acceptability and uptake among users, 
providers, and the health system. Recognizing the important role that providers play in influ-
encing policy as well as services, provider knowledge and attitudes were also seen as import-
ant. Whereas some issues related to providers can be addressed through research, work in 
this area will also involve education and training.
Participants also identified priorities related to product adherence as well as specific topics 
relevant to gel and to rings. It has been challenging to maintain and to measure adherence 
in microbicide trials, and developing and testing approaches to bolstering adherence out-
Select OR Questions
Service Delivery Models, Programs,  
Services 
•	What service model(s) or package is most 
effective for reaching key populations? Under 
what conditions? Which populations? 
•	Which program entry points would be most 
effective to deliver gel/ring (e.g., RH/FP, ANC, 
counseling and testing services, primary 
health care, school health, private sector, 
etc.)?
Providers: Type, Level, Training 
•	What cadre(s) (nurse, clinical officer, health 
worker) of providers is needed to ensure 
appropriate counseling, provision, testing, 
resupply, and follow-up? 
•	What are providers’ attitudes and beliefs 
around ARV-based prevention in general and 
gel/ring in particular? How can these be influ-
enced to facilitate successful introduction? 
HIV Testing and Retesting
•	What are the implications of the need for peri-
odic HIV testing on product acceptability and 
uptake among users, providers, and health 
systems? 
•	What are the acceptability and feasibility of 
different HIV screening and testing approaches 
to: Clients? Providers? The service site? The 
health system overall?
Potential Resistance (understanding, minimiz-
ing, managing)
•	How can potential drug resistance be deter-
mined, minimized, and managed in routine 
services? 
•	What is the realistic risk of resistance with use 
of ARV-containing gels and rings? 
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side of trials was seen as a clear priority, 
though the timing is uncertain. Overall, 
there is less information from trials on 
the ring than gel, and technology-specific 
priorities focused on supporting women 
to understand and use the ring, as well 
as the implications of a sustained-release 
method for adherence, use, and user 
satisfaction. For gel, the priorities were 
somewhat more instrumental, such as 
what amount to provide at each visit, stor-
age for users and the health system, and 
the implications of switching from prefilled 
to user-filled applicators. 
Priorities for user perspectives and educa-
tion centered around how best to commu-
nicate partial effectiveness, and specific 
counseling requirements for initial adop-
tion and ongoing use/resupply of gel and 
rings. Finally, the cost implications of dif-
ferent service models, as well as who will 
pay for the product and programs, were 
seen by some as a priority. Those issues 
that surfaced throughout the meeting are 
discussed in more detail in the following 
sections.
Populations, service types, and service 
settings: Weaving it together 
Determining which service-delivery set-
tings would be most appropriate and 
feasible to reach different user groups—
the heart of operations research—was a 
main theme throughout the consultation. 
Priority user groups would be determined 
by the specific epidemic in a given set-
ting, as would available services on which 
to build. For more specific discussions, 
participants broke into two groups to try 
to define OR studies and begin to map out study designs using the PICOT framework. With 
some differences, both groups proposed and worked through similar broad study outlines to 
explore different dimensions of feasibility, acceptability, cost, and reach of building on exist-
ing services to deliver the gel and/or ring to specific user groups. 
Select OR Questions (con’t)
Adherence: Optimizing and Measuring
•	What strategies or combination of strategies 
(counseling, communications, mobile technol-
ogies) are effective for supporting and bolster-
ing adherence among users?
•	What are feasible approaches to measuring 
or assessing adherence under routine service 
conditions?
Vaginal Ring–Specific Issues
•	How can ring service provision be proactive in 
supporting women’s use of the ring, includ-
ing helping women understand and manage 
potential expulsions?
•	Given that the vaginal ring is not coitally 
dependent and does not require daily action, 
what are the implications for adherence, use, 
user satisfaction?
Vaginal Gel–Specific Issues
•	How will the amount of gel provided to users 
at each visit be determined? Will initial 
and resupply visits take place at the same 
location? 
•	What are the storage implications for gel at the 
service-delivery site? For the user? For logistics 
and supply systems? 
User Perspectives and Education 
•	What do women know about ARV-based pre-
vention? What are their views about the gel/
ring? What are their partners’ views?
•	How can the gel/ring’s partial effectiveness 
best be communicated to users? 
Program Costs 
•	What are the anticipated (or likely) product, 
service, and program costs? Who is expected 
to pay for these costs? 
•	What implications do different program models 
and scenarios have for cost?
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•	 Population: Relevant population groups would be determined by the nature of the 
epidemic in a given setting, and the small groups discussed several possible popula-
tions for initial OR studies. For example, married women in Kenya and young women in 
South Africa were both seen to be likely user groups for ARV-based prevention tech-
nologies. Most participants felt that initial OR studies could and should be focused 
in the communities that hosted gel or ring trials. While located in trial communities, 
OR studies should not be limited to trial participants and, depending on their design, 
should generally not take place in trial clinics. 
•	 Intervention: Priority interventions would focus on different packages of services that 
include HIV testing and retesting with product supply and resupply (for either ring or 
gel). These services would be delivered in different settings such as family planning/
reproductive health services, HIV testing services, and possibly school-based service 
points. 
•	 Comparison: The studies could be designed to compare different service intervals (for 
example providing the same service every three months versus every six months) or 
different service types. 
•	 Outcome: Outcomes could include retention in services, adherence, acceptability, 
and/or cost. One group discussed the emergence of drug-resistant virus as a research 
priority. Some aspects of resistance could be explored through OR while others would 
call for clinical research. Priority “nested” studies to investigate specific issues within 
the context of broader OR efforts could include models for testing, counseling, and 
information provision, and challenges to logistics or supply-chain management. 
•	 Time: The proposed timeframe varied from one to two years, depending on the specific 
intervention. Some participants argued for a timeframe longer than one year given 
that retention in microbicide gel trials dropped off after a year. 
Timing: When to initiate what types of research
It can be difficult to clearly distinguish when operations research is most appropriate and 
fruitful for many issues. Some topics—for example, participants’ understanding of partial 
effectiveness—may lend themselves to research in the context of clinical trials, either as 
a formal part of the trial or an ancillary study. However, findings from studies that employ 
the participants, clinic staff, and resources from trials may have limited relevance for more 
routine service settings. Other priority issues, such as testing different approaches to bol-
stering adherence, may not be possible within randomized controlled clinical trials where 
service interventions need to remain consistent across comparison groups. Studies under 
more routine service settings may not be feasible for products that are not yet licensed in a 
country, though this may be possible in some settings under a research designation. Ideally 
many issues could be explored in clinical trials and ancillary studies, and then further refined 
through operations research in pre-introductory and early rollout phases. However, resource 
constraints may limit such a phased approach. The tension between needing information 
relevant to implementation in routine service settings, and the limitations on conducting 
research in such settings with products that are not yet licensed, will remain. 
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Proxy products: What can we learn from proxies and how can this knowledge be applied? 
Most OR is conducted with available products, and the discussion returned repeatedly to 
the challenging issue of conducting operations research for products under development. 
Both tenofovir gel and the dapivirine ring will be strictly controlled until they are licensed 
and approved by national regulatory authorities. While it may be possible to conduct some 
studies with proxy products, there was considerable debate about the value of research with 
proxy products (for example, the contraceptive vaginal ring or sexual lubricants) for inform-
ing service design, logistics, and other aspects of delivering ARV-containing microbicide 
products. While some participants felt this approach would yield valuable information about 
product introduction and delivery, others noted that the differences—for example in service 
components (such as HIV testing) and motivation of users and providers (to use sexual lubri-
cants compared with tenofovir gel for HIV prevention)—would be so significant that it would 
be difficult to garner useful lessons for microbicide introduction. Given the publicity around 
tenofovir gel in South Africa, for example, it could even be misunderstood that the lubricant is 
tenofovir gel, which could cause confusion and might even put women at risk. This issue was 
not clearly resolved; proxy research may be useful under specific conditions and in different 
settings, but the implications need careful consideration. 
Partial effectiveness: What and how to convey? 
A great deal of discussion surrounded the importance and complexity of conveying partial 
effectiveness to users and policymakers. Generally, participants agreed that shifting both 
the language and concept from “prevention” to “risk reduction” is important as it may allow 
and indeed force a rethinking of the concept of “partial effectiveness” and how it can be 
conveyed in a more affirmative and accurate manner. Such research could draw on other 
examples of interventions that reduce but do not eliminate risk (such as immunization or 
seat belts). A useful step would be to review how partial effectiveness has been explained 
(and understood) in trials to date, and use this information to develop additional research 
on partial effectiveness, including context specific terminology and concepts, outside of trial 
populations. 
Gels and rings: Shared contexts, unique products
Recognizing the different product attributes and use dynamics between gels and rings, 
participants broke into two groups to discuss and identify priority research particular to each 
technology. Given that a number of candidate microbicide gels have been developed and 
tested in Phase 3 trials, much more data and experience with gels exists. Much of the discus-
sion focused on contextual issues: identifying settings, populations, and individuals who are 
at risk and thus could benefit most from the gel; how to ensure that the gel is not stigmatized 
through association with risk groups or behaviors; the possibility of positioning the gel for 
use in intimate partnerships; and innovative approaches to balancing the need for monitor-
ing with ease of access and ensuring women have an adequate supply including the use of 
smart cards, SMS, or other electronic approaches. Priority topics for rings include whether 
women would choose a ring if they were not having sex regularly; the reasons women remove 
rings, and what is done with the ring when it is taken out; and how to convey the impact of 
imperfect use on the ring’s effectiveness.
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Bolstering adherence: How to do it? And then, how to measure it?
Supporting and measuring adherence has been a significant challenge in clinical trials, and it 
is not known whether adherence will be more or less difficult in ongoing use of proven prod-
ucts. While a great deal of thought and effort has gone into improving approaches to measur-
ing adherence, relatively less has been invested in evaluating counseling and strategies for 
improving adherence. Several discussions centered on approaches to bolstering adherence 
and whether different approaches could be compared in the context of a clinical trial as a 
nested study. Given the complexity of implementing trials and keeping variation to a mini-
mum, such adherence studies may not be feasible until bridging or pre-introduction studies. 
One participant noted that specific strategies for improving adherence efforts in trials have 
not been rigorously evaluated and that doing so may be a productive initial step. 
Other cross-cutting issues: Developing champions, civil society engagement 
During the consultation’s lively and wide-ranging discussions, a number of important issues 
surfaced that, while critically important, do not lend themselves to operations research per 
se. For example, discussion returned repeatedly to the best ways to engage providers, who 
need to be informed about research on gels and rings and brought on board as champions. 
Similarly, community and advocacy groups offer important perspectives to inform preparation 
for product introduction and could press governments and donors to invest in new preven-
tion approaches for women. However, appropriately timing such professional and commu-
nity engagement needs to balance ensuring that key constituencies are informed, and feel 
informed, without potentially raising expectations too soon and without a clear plan of action. 
Defining the market, estimating demand, and understanding market segmentation
While not explicitly discussed during the operations research consultation, product develop-
ers working to make tenofovir gel available outlined several critical issues related to estimat-
ing and defining the market and reaching users with the product. The coalition of groups that 
has developed and tested tenofovir gel has come primarily from the public and philanthropic 
sectors driven by a public health imperative. As the product moves through advanced clinical 
testing, these efforts are shifting to estimating and defining the market for tenofovir gel to 
inform manufacturing, investment, and pricing scenarios. Such efforts concern identifying 
potential user groups in different contexts and then more precisely estimating the uptake and 
use of the gel to balance building demand with ensuring adequate supply to meet that as yet 
undefined demand. At the same time, as a product that will likely be subsidized and provided 
chiefly through the public sector, efforts to provide tenofovir gel will depend on programs 
developed, funded, and implemented through the public health sector, and interest and com-
mitment to this needs to be understood and to the extent possible, quantified. 
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LOOKING AHEAD AND MOVING FORWARD
Developing an operations research agenda takes time and is challenging without defined 
products, settings, and populations. The OR consultation engaged its diverse participants in 
grappling with how best to define and prioritize research related to delivering ARV-containing 
gels and rings for women. The process of developing an OR agenda will continue as clinical 
data continue to emerge on ARV-containing gels and rings. Useful data and lessons will also 
emerge from the PrEP demonstration projects now being designed and implemented, and 
it will be important to ensure that some of those projects are developed with an eye to also 
informing introduction of gels and rings. 
Ultimately, the OR agenda for new women-centered prevention will need to be defined by 
key stakeholders within the framework of specific health systems and epidemics. Given the 
timeframe for ongoing clinical research and new approaches like medical male circumcision 
and PrEP that have emerged in the last several years, ARV-containing gels and rings will be 
introduced as an element of combination prevention. As such, new products will need to be 
examined and understood within the range of prevention options available. While developing 
and implementing an OR agenda is a crucial part of preparing for new product introduction, 
ultimately programs will need to move forward without every question answered. This is and 
will continue to be a challenging and dynamic process. 
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APPENDIX 1  
REPORTS AND ARTICLES REVIEWED FOR THE 
CONSULTATION
Document Author/Organization Year
Development and coordination of programmatic 
research on tenofovir gel
WHO, UNAIDS 2011
Report of a consultation: Preparing for pre-exposure  









HIV PrEP: New data and potential use
Topics in Antiviral Medicine  
December 2011/January 2012; (19)5.
C. Celum 2011-
12
Insights and evidence from product introduction:  
Lessons for microbicides
Day of dialogue meeting report 
http://www.popcouncil.org/pdfs/DoDMicrobicides.pdf
M. Brady and E. McGrory 
Population Council 
2007
Planning for PrEP 




Imperial College, Gates 
Foundation 
2009 
Microbicide access forum meeting  IPM, USAID, WHO 2007
Microbicide access forum meeting report IPM, Population Council, 
USAID, WHO
2008
Microbicide access forum meeting report IPM, USAID, WHO 2009
Mind the gap: Summary of microbicide access forum IPM, WHO, UNAIDS, AVAC 2011
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Document Author/Organization Date
Stakeholder meeting on pre-exposure prophylaxis WHO, UNAIDS, Imperial 
College London, London 
School of Hygiene and 
Tropical Medicine, and 
Georgetown University 
2011
Packaging PrEP to prevent HIV: An integrated  
framework to plan for pre-exposure prophylaxis  
implementation in clinical practice
Journal of Acquired Immune Deficiency Syndromes 2010; 
55(1):8-13.
K. Underhill et al. 2010
Designing HIV/AIDS Intervention Studies:  
An Operations Research Handbook 
http://www.popcouncil.org/pdfs/horizons/orhivaidsh-
ndbk.pdf 
A. Fisher et al. 
Population Council
2002
What works for women and girls: evidence for HIV/
AIDS interventions 
www.whatworksforwomen.org
J. Gay et al.  
Open Society Institute 
2010
Pre-exposure prophylaxis state of the science:  
Empirical analogies for research and implementation
Current HIV/AIDS Reports 2010; 7(4): 201–209. 
http://www.ncbi.nlm.nih.gov/pmc/articles/
PMC2938422/?tool=pubmed
S.A. Golub, D. Operario 
and P.M. Gorbach 
2010
Microbicide acceptability research: recent findings and 
evolution across phases of product development 
Current Opinion in HIV and AIDS 2008; 3(5): 581–586.
A. Coly and P. Gorbach 2008
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APPENDIX 2  
QUESTIONS FOR EXPERT REVIEW
These pages contain the full set of questions sent to participants prior to the meeting for 
review and prioritization. Council staff reviewed and compiled the feedback to serve as a 






I. Service Delivery Models, Programs, Services 
1. What service model(s) or package is most effective for 
reaching key populations? Under what conditions? Which 
populations? 
2. Which program entry points would be most effective to 
deliver gel/ring (e.g., RH/FP, ANC, counseling and testing 
services, primary health care, school health, private sector, 
etc.)?
3. What are the resource requirements of different program 
delivery approaches?
4. How do counseling needs for gel/ring fit within counseling 
needs for other services? 
5. How does providing the new product (gel or ring) affect exist-
ing services in terms of client flow, operations, staffing, etc.?
6. What are the implications of the need for medical monitoring 
for provider and service type?
II. Providers: Type, Level, Training 
1. What cadre(s) (nurse, clinical officer, health worker) of provid-
ers are needed to ensure appropriate counseling, provision, 
testing, resupply and follow-up? 
2. What are providers’ attitudes and beliefs around ARV-based 
prevention in general and gel/ring in particular? How can 
these be influenced to facilitate successful introduction? 
3. What is the lowest level of health care provider suitable to 
ARV-based gel or ring implementation? 
4. What is the role of supervision in ensuring the fidelity of infor-
mation/messages and the quality of service provision?






III. HIV Testing and Retesting
1. What are the implications of the need for periodic HIV testing 
on product acceptability and uptake among users, providers, 
and health systems? 
2. What are the acceptability and feasibility of different HIV 
screening and testing approaches to: Clients? Providers? The 
service site? The health system overall?
3. What education strategies are most effective in conveying to 
users the importance of regular retesting for HIV? Does this 
correlate with actual retesting?
4. What are the implications of HIV testing and retesting for 
cost and cost effectiveness? 
IV. Potential Resistance (understanding, minimizing, 
managing)
1. How can potential drug resistance be determined, mini-
mized, and managed in routine services? 
2. What is the realistic risk of resistance with use of ARV-  
containing gels and rings? 
3. What is the feasibility of monitoring resistance?
V. Adherence: Optimizing and Measuring
1. What are the patterns of use and use dynamics under “rou-
tine” conditions? 
2. What strategies or combination of strategies (counseling, 
communications, mobile technologies) are effective for sup-
porting and bolstering adherence among users? 
3. What are feasible approaches to measuring or assessing 
adherence under routine service conditions?
VI. Vaginal Ring–Specific Issues
1. How can ring service provision be proactive in supporting 
women’s use of the ring, including helping women under-
stand and manage potential expulsions?
2. What are the implications of toileting and hygiene practices 
for the use of vaginal rings? 
3. What is the feasibility of women (in a given setting) caring for, 
washing, and storing the ring in a safe, discreet place? 
4. Given that the vaginal ring is not coitally dependent and does 
not require daily action, what are the implications for adher-
ence, use, user satisfaction?






VII. Vaginal Gel–Specific Issues
1. How will the amount of gel provided to users at each visit be 
determined? Will initial and resupply visits take place at the 
same location? [For specific setting, user groups?]
2. What are the storage implications for gel at the service deliv-
ery site? For the user? For logistics and supply systems? 
3. What are key messages for users around leakage, lubrica-
tion, hygiene, douching, and other vaginal practices? 
4. What are the best ways to ensure that clients understand 
and correctly use the gel? In pre-filled applicators? In  
user-filled paper applicators?
VIII. User Perspectives and Education 
1. What do women know about ARV-based prevention? What 
are their views about the gel/ring? What are their partners’ 
views?
2. How can the gel/ring’s partial effectiveness best be  
communicated to users? 
3. What are the specific requirements for counseling and user 
education for gel or ring use? For initial adoption? For ongo-
ing use and resupply? 
4. Will gel and rings be explicitly marketed to different user 
groups? If so, how will they be identified? If not, how will the 
different technologies be provided/described as part of a 
package of prevention?
IX. Program Costs 
1. What are the anticipated (or likely) product, service, and 
program costs? Who is expected to pay these costs? 
2. What implications do different program models and  
scenarios have for cost?
3. What is the marginal cost of adding the product (gel or ring) 
to a given program or system?
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CONSULTATION AGENDA
MONDAY, JUNE 18
 9:00 a.m. Coffee & continental breakfast (provided)
 9:30 – 10:00 Meeting Content and Context Martha Brady, Population  
Council 
David Stanton, U.S. Agency for  
International Development




What works for HIV prevention for  
women? A review of the evidence 
What have we learned from other health 
technologies: How do they work for women? 
Discussion, Q and A
Co-Chairs: Naomi Rutenberg,  
Population Council and  
Nono Simelela, The Presidency- 
South Africa 
Fitih Bicha, Futures Group
 
Martha Brady, Population 
Council 
11:00 – 11:15 Coffee/tea break
11:15 – 12:30 ARV-based Prevention Products for Women 
Overview of clinical trials, product pipelines, 
and timelines
Gels and rings: Where are we? 
Questions and clarification 
Acceptability of rings and gels
Discussion, Q and A
Chair: Elizabeth Bukusi, Kenya  
Medical Research Institute
Manju Chatani-Gada, AVAC:  
Global Advocacy for HIV 
Prevention
Joe Romano, Consultant, Bill &  
Melinda Gates Foundation
Cynthia Woodsong, International  
Partnership for Microbicides
12:30 – 1:30 Lunch (provided)




Key outstanding issues with tenofovir gel  
 
WHO guidance: What evidence is needed?
Operations research: What it can and can-
not do
Chair: Helen Rees, Wits  
Reproductive Health and HIV  
Research Institute 
Tim Farley, Sigma3 Services, 
World Health Organization 
Consultant 
Ian Askew, Population Council/
Kenya
3:00 – 3:15 Coffee/tea break
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3:15 – 5:15 
3:15 – 4:00 
4:00 – 5:15
Review and Generate OR Questions
Presentation of research topics and ques-
tions: Feedback from participants 
Discussion and vetting of broad OR ques-
tions for ARV-based prevention products for 
women
ARV-based gels and rings:  
Small groups 
• Gel group
• Ring group 
Wrap up and instructions for Day Two 
Facilitator: Saiqa Mullick,  
Population Council/South Africa
Sam Kalibala, Population  
Council 
Facilitators: Sengeziwe Sibeko 
and Leila Mansoor  
Facilitators: Elizabeth Bukusi 
and Cynthia Woodsong
 5:30 p.m. Adjourn and reception at  
Population Council
TUESDAY, JUNE 19 
 8:30 a.m. Coffee & continental breakfast (provided)
 9:00 –11:00 Roundup of Questions and Issues 
 
Re-cap of Day One
Report back: Key questions on gels and 
rings 
Vetting and prioritization
Facilitator: Lori Heise, London 
School of Hygiene & Tropical 
Medicine
Elizabeth McGrory, Consultant 
Rapporteurs from groups 
Meeting participants 
11:00 – 11:15 Coffee/tea break
11:15 – 12:45 Marrying Research Questions with Re-
search Designs
Group discussion
Facilitators: Avina Sarna,  
Population Council/India and 
Ian Askew
12:45 – 2:00 Lunch (provided)
 2:00 – 3:00 Wrap Up and Next Steps David Stanton, Martha Brady
 3:00 – 5:00 Optional tour of Population Council’s Center 
for Biomedical Research (CBR) laboratories 
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